rotundiogenin A | 79786-12-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: rotundiogenin A
• 英文别名: (1S,2R,4S,5R,8R,10S,13S,14R,17S,18R)-4,5,9,9,13,20,20-heptamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracos-15-ene-2,10-diol
• CAS: 79786-12-2
• 化学式: C₃₀H₄₈O₃
• 分子量: 456.709
• InChiKey: IUXCCCANLLMMGX-DNSXXVLGSA-N

物化性质

• 沸点：
  551.6±50.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  33
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  rotundiogenin A 在 platinum(IV) oxide 氢气 作用下， 以 溶剂黄146 为溶剂， 反应 5.0h， 生成 报春花甙元
  参考文献：
  名称：

  New triterpenoid glycosides from the leaves of Bupleurum rotundifolium L.

  摘要：

  从Bupleurum rotundifolium L.叶片中分离出的两种新的齐墩果烷型三萜类化合物--罗汉果苷E (3)和F (1)，被鉴定为16α, 28-二羟基油菜-11, 13 (18)-dien-3β-yl α-L→2）-β-吡喃葡萄糖基被鉴定为 16α，28-二羟基油菜-11，13 (18)-二烯-3β-基 α-L-鼠李糖基-(1→2)-β-D-吡喃葡萄糖基-(1→2)-β-D-吡喃葡萄糖苷 (3) 和 13β、28-epoxy-16α-hydroxyoleana-11-en-3β-yl α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranosyl-(1→2)-β-D-fucopyranoside (1)。

  DOI：

  10.1248/cpb.29.2222
• 作为产物：
  描述：

  报春花甙元 在 sodium acetate 、 对甲苯磺酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 6.5h， 生成 rotundiogenin A
  参考文献：
  名称：

  Yoshikawa, Masayuki; Wang, Hui Kang; Tosirisuk, Veeraphan, Chemical and pharmaceutical bulletin, 1982, vol. 30, # 8, p. 3057 - 3060

  摘要：

  DOI：

文献信息

• Polynucleotide binding complexes comprising sterols and saponin
  申请人：Nordic Vaccine Technology A/S

  公开号：EP2011517A1

  公开（公告）日：2009-01-07

  The present invention pertains to complexes comprising sterols and saponins. The complexes are capable of binding a genetic determinant including a polynucleotide. The complexes may further comprise a lipophilic moiety, optionally a lipophilic moiety comprising a contacting group and/or a targeting ligand, and/or a saccharide moiety. The complexes may further comprise an immunogenic determinant and/or an antigenic determinant and/or a medicament and/or a diagnostic compound. The complexes may in even further embodiments be encapsulated by an encapsulation agent including a biodegradable microsphere. The present invention also pertains to pharmaceutical compositions and methods of treatment of an individual by therapy and/or surgery, methods of cosmetic treatment, and diagnostic methods practised on the human or animal body.

  本发明涉及由甾醇和皂甙组成的复合物。这些复合物能够结合包括多核苷酸在内的遗传决定因子。复合物可进一步包含亲脂分子，可选择包含接触基团和/或靶向配体的亲脂分子和/或糖分子。复合物可进一步包括免疫原决定簇和/或抗原决定簇和/或药物和/或诊断化合物。在更进一步的实施方案中，复合物可被包括生物可降解微球在内的封装剂封装。本发明还涉及通过治疗和/或手术对个体进行治疗的药物组合物和方法、美容治疗方法以及对人体或动物体进行诊断的方法。
• POLYNUCLEOTIDE BINDING COMPLEXES COMPRISING STEROLS AND SAPONINS
  申请人：Nordic Vaccine Technology A/S

  公开号：EP1377320B1

  公开（公告）日：2008-10-01
• THERAPEUTICAL VACCINATION
  申请人：Nordic Vaccine Technology A/S

  公开号：EP1409009A1

  公开（公告）日：2004-04-21
• PARTICLE STRUCTURES COMPRISING STEROLS AND SAPONINS
  申请人：DALSGAARD Kristian

  公开号：US20110020226A1

  公开（公告）日：2011-01-27

  The present invention pertains to complexes comprising sterols and saponins. The complexes are capable of binding a genetic determinant including a polynucleotide. The complexes may further comprise a lipophilic moiety, optionally a lipophilic moiety comprising a contacting group and/or a targeting ligand, and/or a saccharide moiety. The complexes may further comprise an immunogenic determinant and/or an antigenic determinant and/or a medicament and/or a diagnostic compound. The complexes may in even further embodiments be encapsulated by an encapsulation agent including a biodegradable microsphere. The present invention also pertains to pharmaceutical compositions and methods of treatment of an individual by therapy and/or surgery, methods of cosmetic treatment, and diagnostic methods practised on the human or animal body.
• US7713942B2
  申请人：——

  公开号：US7713942B2

  公开（公告）日：2010-05-11